Accelerated development of appropriate patient therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes
Project factsheets
The Innovative Health Initiative builds on the successes of the Innovative Medicines Initiative (IMI), which launched over 180 projects. Many IMI projects are still ongoing and are monitored by the IHI Programme Office. This section features the factsheets of all IMI projects. Once IHI projects are up and running, we will also promote them here.
Displaying 34 projects/programmes
Antimicrobial Resistance Accelerator
Amyloid imaging to prevent Alzheimer’s disease
conect4children - Collaborative network for European clinical trials for children
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Collaboration for prevention and treatment of MDR bacterial infections
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen
Electronic Health Records Systems for Clinical Research
European prevention of Alzheimer’s dementia consortium
European Autism Interventions - a Multicentre Study for Developing New Medications
EU patient-centric clinical trial platform
Understanding chronic pain and improving its treatment
Framework for clinical trial participants data reutilization for a fully transparent and ethical ecosystem
Incorporating real-life clinical data into drug development
The GetReal Initiative
Inhaled antibiotics in bronchiectasis and cystic fibrosis
Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases
Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes.
Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA
New Drugs for Bad Bugs
New clinical endpoints in primary Sjögren’s syndrome: an interventional trial based on stratifying patients
Novel methods leading to new medications in depression and schizophrenia
Patients active in research and dialogues for an improved generation of medicines: advancing meaningful patient engagement in the life cycle of medicines for better health outcomes
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
Model-based preclinical development of anti-tuberculosis drug combinations
Patient Preferences in benefit risk assessments during the drug life cycle
Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD
Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools
Center of excellence – remote decentralised clinical trials
Academia and industry united innovation and treatment for tuberculosis
